(Q53814708)

http://europepmc.org/abstract/MED/26439378

20 May 2018

title

Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer. (English)

1 reference

http://europepmc.org/abstract/MED/26439378

20 May 2018

author

Yongfeng Li

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26439378%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Xuli Meng

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26439378%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Hongchao Tang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26439378%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Weimin Mao

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26439378%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Hongjian Yang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26439378%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Xiaojia Wang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26439378%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Xianfeng Ding

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26439378%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Shangnao Xie

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26439378%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

6 October 2015

1 reference

http://europepmc.org/abstract/MED/26439378

20 May 2018

published in

Amino Acids

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26439378%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26439378%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26439378%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

487-497

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26439378%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00726-015-2102-2

4 June 2020

exact match

0 references

cites work

A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

21 January 2018

The Protein Data Bank

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

The changing global patterns of female breast cancer incidence and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

Cannabinoids: a new hope for breast cancer therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

Investigating the substrate specificity of the HER2/Neu tyrosine kinase using peptide libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

Lapatinib in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

Comparison of simple potential functions for simulating liquid water

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

Improved prediction of protein side-chain conformations with SCWRL4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

Development and testing of a general amber force field

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

Specific noncovalent interactions at protein-ligand interface: implications for rational drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-015-2102-2

Free Energy Calculations by the Molecular Mechanics Poisson-Boltzmann Surface Area Method

21 January 2018

1 reference

COCI

https://opencitations.net/index/coci/api/v1/citations/10.1002/MINF.201100135

10.1007/S00726-015-2102-2

10 April 2023

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26439378%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference